What To Expect From Pfizer In The Post-COVID-19 Era


  • In Q4 2022, the company’s revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people’s desire to vaccinate against COVID-19.
  • According to the Wall Street Journal, Pfizer’s management is in talks to acquire Seagen to expand the company’s portfolio with promising cancer-fighting medicines.
  • Paxlovid sales amounted to $1,834 million in Q4 2022, showing a significant increase compared to the previous year.
  • Pfizer’s current dividend yield of 4.04% is not only significantly higher than the largest pharmaceutical companies but outperforms other sector leaders such as Procter & Gamble and Coca-Cola.
  • This article will present the factors that make the company an attractive asset for dividend investors and the risks that anyone considering Pfizer as a long-term investment should be aware of.
Здоровая молодая женщина, принимая травяные добавки

Drazen_/E+ via Getty Images

Pfizer (NYSE:NYSE:PFE) is one of the largest pharmaceutical companies in the world, specializing in the development and manufacture of medicines for the treatment of a wide range of diseases, such as cardiovascular diseases, cancer, and autoimmune diseases, and a vaccine portfolio for the prevention

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sell securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.

Leave a Reply

Your email address will not be published. Required fields are marked *